Vischer advised Atanis Biotech, a Swiss biotechnology company, to successful completion of an oversubscribed financing round. The financing round The proceeds from this operation will fund the European and North-American marketing campaigns for Atanis’s “
Search Results for: vischer
Vischer advised Chinese companies Kelun-Biotech and Harbour BioMed in all Swiss law matters of a licencing agreement. Moreover, the Swiss law firm assisted RTW, an investor, within the seed financing round of Winward Bio, the
As of January 2025, Anela Lucic (pictured) has been promoted to partner at Vischer, a firm she has been part of since 2014. The profile Anela Lucic’s area of practice includes advising and representing national and
Walder Wyss advised Migros on its sale of Gowoonsesang Cosmetics, a South Korean subsidiary of the MIbelle group, to L’Oréal. The transaction is expected to be completed after customary regulatory approvals. The team
Advestra advised Liberta Partner, a Munich-based multi-family office, on its acquisition of a majority stake in Avenir Group, a human resource management company headquartered in Switzerland, advised by Vischer. Furthermore, Baker McKenzie advised Migros Bank
Vischer advised Ikerian, a healthcare software platform company, on its first round of USD 8m Series B financing to advance its AI platform. The Series B financing round is led by strategic investor Sanoptis led
Vischer has acted as legal advisor to MegaCAD GmbH in its acquisition of Bausoft Informatik AG, a leading Swiss software company specialising in CAD solutions for the building engineering sector. Since its founding in 1994, Bausoft
Vischer acted as Swiss counsel to the founders of Santis Pharma on its partnership with Abenex, in collaboration with lead counsel Archer Avocats. Accompanied by its new partner, Santis Pharma aims at accelerating its expansion
Vischer advised Haya Therapeutics, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, which announced a multi-year agreement with Eli Lilly and Company to apply Haya’s advanced RNA-guided regulatory genome platform to
Walder Wyss advised SkyCell on its USD 116 million Series D financing round. It embarked on a USD 57 million equity investment by M&G Investments in October 2023 and has now been completed with further investments